Polar Capital Global Healthcare Trust plc (PCGH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polar Capital Global Healthcare Trust plc (PCGH) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-305.00K ≈ $-37.11 USD) by net assets (GBX448.11 Million ≈ $54.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Polar Capital Global Healthcare Trust plc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Polar Capital Global Healthcare Trust plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Polar Capital Global Healthcare Trust pl total liabilities for a breakdown of total debt and financial obligations.
Polar Capital Global Healthcare Trust plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polar Capital Global Healthcare Trust plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIMFABRIC SA ZY-10
F:853
|
0.139x |
|
Archon Minerals Ltd
V:ACS
|
-0.007x |
|
Marquee Resources Ltd
AU:MQR
|
-0.132x |
|
KST Beteiligungs AG
F:KSW
|
N/A |
|
Metals Exploration Plc
LSE:MTL
|
0.157x |
|
Carmell Therapeutics Corporation
NASDAQ:CTCX
|
0.198x |
|
Bold Ventures Inc
V:BOL
|
-0.119x |
|
Asia Fiber Public Company Limited
BK:AFC
|
0.050x |
Annual Cash Flow Conversion Efficiency for Polar Capital Global Healthcare Trust plc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Polar Capital Global Healthcare Trust plc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Polar Capital Global Healthcare Trust pl (PCGH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | GBX448.11 Million ≈ $54.52K |
GBX-1.43 Million ≈ $-173.87 |
-0.003x | -5192.46% |
| 2024-09-30 | GBX479.07 Million ≈ $58.29K |
GBX30.00K ≈ $3.65 |
0.000x | +101.15% |
| 2023-09-30 | GBX419.18 Million ≈ $51.00K |
GBX-2.29 Million ≈ $-278.51 |
-0.005x | +40.95% |
| 2022-12-31 | GBX404.83 Million ≈ $49.26K |
GBX-3.74 Million ≈ $-455.54 |
-0.009x | 0.00% |
| 2022-09-30 | GBX404.83 Million ≈ $49.26K |
GBX-3.74 Million ≈ $-455.54 |
-0.009x | -129.82% |
| 2021-12-31 | GBX422.19 Million ≈ $51.37K |
GBX-1.70 Million ≈ $-206.72 |
-0.004x | +8.64% |
| 2021-09-30 | GBX385.73 Million ≈ $46.93K |
GBX-1.70 Million ≈ $-206.72 |
-0.004x | -110.89% |
| 2020-12-31 | GBX360.54 Million ≈ $43.87K |
GBX14.58 Million ≈ $1.77K |
0.040x | -9.82% |
| 2020-09-30 | GBX325.13 Million ≈ $39.56K |
GBX14.58 Million ≈ $1.77K |
0.045x | +1110.61% |
| 2019-09-30 | GBX288.45 Million ≈ $35.10K |
GBX-1.28 Million ≈ $-155.74 |
-0.004x | -109.19% |
| 2018-09-30 | GBX296.26 Million ≈ $36.05K |
GBX14.30 Million ≈ $1.74K |
0.048x | +130.98% |
| 2017-09-30 | GBX250.13 Million ≈ $30.43K |
GBX-38.99 Million ≈ $-4.74K |
-0.156x | -452.71% |
| 2016-09-30 | GBX247.82 Million ≈ $30.15K |
GBX10.95 Million ≈ $1.33K |
0.044x | +22.77% |
| 2015-09-30 | GBX210.44 Million ≈ $25.60K |
GBX7.58 Million ≈ $921.66 |
0.036x | +154.94% |
| 2014-09-30 | GBX199.96 Million ≈ $24.33K |
GBX-13.10 Million ≈ $-1.59K |
-0.066x | -81.49% |
| 2013-09-30 | GBX155.75 Million ≈ $18.95K |
GBX-5.62 Million ≈ $-684.16 |
-0.036x | -19.85% |
| 2012-09-30 | GBX120.74 Million ≈ $14.69K |
GBX-3.64 Million ≈ $-442.52 |
-0.030x | -- |
About Polar Capital Global Healthcare Trust plc
Polar Capital Global Healthcare Trust plc is a closed ended equity mutual fund launched and managed by Polar Capital LLP. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, with an emphasis on companies involved in pharmaceuticals, medical services, medical devices, and biotechnology. The fund primarily invests… Read more